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Abstract
We have examined the effects of the beta-amyloid peptide (Ah25 –35) on fibroblasts derived from subjects with Alzheimer’s disease (AD)
and from age-matched controls. The peptide was significantly more cytotoxic to the AD-derived fibroblasts. The level of protein oxidation
was also greater in the cells from AD subjects. Two-dimensional electrophoresis (2-DE) coupled with immunostaining for protein
carbonylation revealed specific oxidation-sensitive proteins (OSPs) in both the control and AD-derived cells. Two specific OSPs were
identified by mass spectrometry as heat shock protein 60 (HSP 60) and vimentin. Exposure of the cells to Ah25 –35 resulted in a twofold
increase in the level of oxidation of these two OSPs in the cells derived from controls, but a ninefold increase in their level of oxidation in the
fibroblasts from AD subjects. These observations are of particular interest because of the proposed anti-apoptotic roles of both HSP 60 and
vimentin and our recent observation that these same two proteins are particularly susceptible to oxidation in neuronally derived cells.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
The neuropathological hallmarks of Alzheimer’s disease
(AD) are accumulation of extracellular amyloid senile
plaques and intracellular neurofibrillary tangles. The main
constituent of senile plaques is beta-amyloid (Ah), which is
believed to induce or exacerbate oxidative stress that is
central to the pathology [1–4]. Studies have shown an
elevated oxidative modification of proteins, lipids, and
DNA in the brain of AD subjects [5,6]. Ah has been shown
to cause both neuronal membrane peroxidation and protein
oxidation, and its cytotoxicity is prevented by antioxidants
[7,8]. Although the neurotoxic activity of Ah is thought to
be mediated by hydrogen peroxide and perhaps other
reactive oxygen species (ROS) [9,10], the cellular targets
of Ah-mediated oxidations remain unclear.
Side chains of virtually all types of amino acids in
proteins can be oxidized, but the susceptibility of protein
to oxidative modification is highly dependent on its
sequence and overall structure [1]. Oxidation can alter
protein functions in many ways (e.g. directly modifying
catalytic amino acids, critical residues in binding sites, or
regulatory sites; and by changing proteolytic susceptibility,
states of aggregation, etc.). Therefore, identification of
specific oxidation-sensitive proteins (OSPs) may provide
important clues to understanding of the role of oxidative
damage in the pathology of the disease.
Although AD is generally considered a neurological
disorder, numerous changes in tissues other than brain of
AD patients have been reported, suggesting that it is
systemic. For example, peripheral abnormalities include
mitochondrial uncoupling, deficiencies in several key
enzymes, altered oxidative metabolism, abnormal amyloid
precursor protein metabolism, and altered calcium homeo-
stasis in platelets and other blood cells [11–13]. Thus,
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fibroblasts from Alzheimer’s subjects may provide a cellular
model system in which the effects of amyloid beta protein
on protein oxidation can be monitored in the dynamic state
and provide information on the mechanism of pathogenesis.
In this study, we investigated the effect of the 11-residue
beta-amyloid peptide (Ah25–35) on protein oxidation and
cytotoxicity in fibroblasts from AD subjects and age-
matched controls. Furthermore, we sought to identify the
critical OSPs that are susceptible to oxidative damage in
cells from AD subjects. To achieve this, we separated
proteins by two-dimensional electrophoresis (2-DE) and
immunostained with an anti-DNP antibody to visualize
oxidized proteins [14]. The most easily oxidized proteins
were identified by mass spectrometry.
2. Materials and methods
2.1. Chemicals
Sodium dodecyl sulfate (SDS), 2,4-dinitrophenylhydra-
zine (DNPH), urea, acrylamide, HCl, glutaraldehyde, form-
aldehyde, Tris-base, and other general chemicals suitable for
electrophoresis were purchased from Fisher Scientific
(Houston, TX) or VWR Scientific Products (Houston, TX).
2.2. Cell culture
Human skin fibroblasts were obtained from the Coriell
cell repository (Camden, NJ). These cells were cultured as
described previously [15] using standard Dulbecco’s modi-
fied eagle medium (DMEM) with 10% (w/v) fetal bovine
sera and gentomycin. Cells were maintained in T-75 flasks
until they were confluent.
2.3. Beta-amyloid (Ab25–35) treatment
Ah25–35 peptide was dissolved in sterile water to a
concentration of 1 mg/ml and diluted with media to the
desired concentrations. It should be noted that the smaller
cytotoxic Ah25–35 peptide was used rather that the full
Ah1–42 and at higher concentrations than exist in vivo. The
specificity of the toxicity of the peptide was confirmed since
use of the reverse sequence (Ah35–25) was nontoxic under
these conditions. For cell viability studies, the day before an
experiment, cells were plated in 96-well plates at a density
of 4 103 cells per well. For protein separation by two-
dimensional polyacrylamide gel electrophoresis (2D-
PAGE), cells were plated in 100-mm culture dishes at a
density of 2 106 cells per plate. The cells were treated with
Ah25–35 at a final concentration of 94 AM.
2.4. Cell viability
Cell viability was measured using a formazan assay kit
(Promega, Madison, WI) [16]. The conversion of MTS into
the aqueous soluble formazan by the dehydrogenases in
metabolically active cells was quantified from the absorb-
ance at 490 nm. In order to correct for growth that occurred
during experiments, absorbance values for treated cells were
divided by the respective absorbance values for nontreated
cells.
2.5. Measurement of ROS generated by Ab25–35
ROS generated intracellularly were assessed using the
probe 2V, 7V-dichlorofluorescin diacetate (DCFH-DA)
(Molecular Probes Inc., Eugene, OR). DCFH-DA is freely
permeable and enters the cell where cellular esterases
hydrolyze the acetate moieties, trapping the polar DCFH
in the cell. ROS in the cells oxidize the DCFH, yielding the
fluorescent product 2V, 7V-dichlorofluorescin (DCF) [17].
Cells were seeded into 96-well plates as described above.
On the third day of the incubation with Ah25–35, DCFH-DA
loading-medium was added (containing DCFH-DA at 50
AM). The cells were incubated in 5% CO2/95% air at 37 jC
for 45 min. After removing the excess DCFH-DA, cells
were washed twice with phosphate buffered saline (PBS)
and incubated in phenol red-free DMEM medium contain-
ing 10% (v/v) FBS. The fluorescence of the cells was
measured with a Bio-Tek microplate fluorescence reader
FL-600 with excitation at 485F 20 nm and emission at
530F 25 nm.
2.6. Sample preparation
Approximately 2 106 cells were plated in 100-mm
plates, allowed to attach for 12 h, and then exposed to the
different experimental conditions. Cells were then trypsi-
nized, collected via centrifugation (1000 g, 10 min),
washed three times in PBS, and recollected by centrifuga-
tion. The cellular pellet was then dissolved in dSDS buffer
[0.3% (w/v) SDS; 1% (w/v) BME; 0.05 M Tris–HCl, pH
8.0] and passed through a 22-gauge needle 10 times. The
extract was placed in boiling water for 3 min and then
transferred to ice for 10 min. Protease inhibitor cocktail
(Completek, Fisher), DNase (M610A: Promega), and
RNase (732-6349: Bio-Rad, Hercules, CA) were added,
and the solution placed at 37 jC for 1 h. Particulates were
removed by centrifugation (15,000 g, 15 min), and the
supernatant solution was collected. Because the dSDS
solution interferes with protein quantification, proteins in a
20-Al aliquot were precipitated with TCA and the precipitate
reconstituted in BCA protein reagent [18] (Pierce, Rockford,
IL).
2.7. Isoelectric focusing and 2D-PAGE
Protein samples (250 Ag) were absorbed onto 18-cm
immobilized pH gradient (IPG) strips (pH 5–6) in an IPG
re-swelling tray, and the strips then isoelectrically focused
on a Multiphor II (Amersham Biosciences, Piscataway, NJ)
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for 24,000 V/h [19]. Following isoelectric focusing the
strips were immediately DNP-derivatized (as described
below), then subjected to equilibration for 15 min in 50
mM Tris–HCl (pH 8.8) containing 6 M urea, 2% (w/v)
SDS, 30% (v/v) glycerol, and 1.0% (w/v) dithiothreitol.
Strips were then re-equilibrated for 15 min in the same
buffer containing 2.5% (w/v) iodoacetamide in place of
dithiothreitol. In all cases, molecular weight separation was
achieved using the ISO-DALT slab gel SDS-PAGE system
(Amersham Biosciences).
2.8. Derivatization of protein carbonyls
Protein samples were derivatized by the ‘‘in-strip DNP
derivatization method’’ of Conrad et al. [14]. Following
rehydration and isoelectric focusing, the IPG strips were
placed in 25-ml test tubes and incubated for 15 min in 2
N HCl/10 mM DNPH at 25jC. After the reaction, the
strips were washed once with 2 M Tris-base/30% (v/v)
glycerol for 15 min. Sample IPG strips were then
prepared for molecular weight separation as described
above.
2.9. SyproR Ruby protein gel stain staining
Duplicate samples of the derivatized proteins were sep-
arated on SDS gradient-polyacrylamide gels (e.g. 9–15%
porosity polyacrylamide). Proteins in one gel were stained
with SyproR Ruby protein gel stain (Bio-Rad), while
proteins on the duplicate gel were electroblotted to poly-
vinylidene difluoride (PVDF) membranes using the ISO-
DALT system. Proteins were first fixed in the gel using 40%
methanol/10% acetic acid (v/v) for 30 min. The protein gel
was then incubated in SyproR Ruby protein gel stain
solution overnight and subsequently destained using 10%
methanol/ 6% acetic acid (v/v) for 45 min. The gels were
placed in a light-tight cabinet directly on a transilluminator;
the dye was then excited with UV light at 365 nm and a
cooled, computerized CCD camera-based imaging system
(Alpha Innotech Corporation, San Leandro, CA) was used
to record the fluorescence.
2.10. DNP-immunostaining
The PVDF membranes were removed from the ISO-
DALT electroblotting apparatus and incubated for 1 h with
5% (w/v) skim milk powder dissolved in PBS containing
3% (v/v) Tween (PBS–Tween). Membranes were incubated
overnight at 4 jC with the anti-DNP primary antibody
(Molecular Probes) solution [1:16,000 dilution in PBS–
Tween containing 5% (w/v) milk] as described previously
[20]. The membranes were then washed three times (15 min
each) with PBS–Tween, incubated for 1 h at 4 jC with a
1:16,000 dilution of the goat anti-rabbit [horse radish
peroxidase (HRP) conjugated] secondary antibody (Sigma,
St. Louis, MO) in PBS–Tween containing 5% (w/v) milk,
and subsequently washed three times (15 min each) with
PBS–Tween. A chemiluminescence kit (SuperSignal West
Femto Maximum Sensitivity Substrate; Pierce) and a
cooled, computerized CCD camera-based imaging system
(Alpha Innotech) were used to visualize and record the
stained proteins.
2.11. Protein image analysis and 2-DE database
The digitized images from the gels stained with SyproR
Ruby for total protein, and from the immunostained blots,
were analyzed using the 2-DE gel analysis program Melanie
3 (Geneva Bioinformatics, Geneva, Switzerland). A com-
parison report of qualitative and quantitative differences of
specific proteins on each gel set of data was then generated.
Table 1
Cytotoxicity of Ah25 – 35 to fibroblasts from Alzheimer’s subjects
Cell line ID# Diagnosis Donor age Percent cell survival in the presence of Ah25 – 35
Incubation time
24 h 48 h 72 h 96 h*
AG 14048 Control 71 108F 20 104F 8 89F 7.9 77F 8.9
AG 13245 Control 68 99F 15.7 100F 12.4 86F 11.4 75F 6.4
AG 13983 Control 71 98F 17.3 100F 14 92F 6.6 83F 13.1
AG 07374 AD (clinically) 73 105F 14.4 102F 15.7 81F 9.9 54F 5.1
AG 08243 AD (clinically) 72 96F 12 106F 9 85F 8.1 46F 7.3
AG 08527 AD (autopsy confirmed) 61 99F 8 98F 11 82F 10.1 47F 9.6
The percent cell survival for each time point was corrected for the growth of the cells by dividing the absorbance value of the treated cells (Ah25 – 35) by the
absorbance value of the corresponding nontreated cells. The value of percent cell survival is the mean of seven samples.
*Cell death of the fibroblasts from AD increased significantly (p < 0.001 by ANOVA) compared to control fibroblasts at 96-hour time point.
Table 2
Reactive oxygen species generation
Fibroblasts 2,7-DCF fluorescence/MTS
Non-AD control 1.26F 0.05
AD 1.24F 0.037
Fibroblasts were incubated in 94 AM Ah25 – 35 for 3 days. Levels of cellular
oxidative stress generated by beta-amyloid were measured relative to
control cells incubated in the absence of Ah25 – 35. ROS were measured
from fluorescence of DCF as described in Materials and methods and are
expressed as relative fluorescence intensity per level of cell viability as
measured by the MTS assay. Values are meansF S.E. of nine samples.
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2.12. Mass spectrometry analysis
Spots of interest were excised from the gel and digested in
situ with trypsin (modified; Promega). The resulting digests
were analyzed by mass spectrometry (MALDI-TOF/MS
using an Applied Biosystems Voyager DE-STR and capil-
lary-HPLC-ESI/MS/MS on a Thermo Finnigan LCQ). The
peptide mass maps produced by MALDI-TOF/MS were
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searched against the published databases by means of the
MS-Fit module in Protein Prospector http://prospector.ucsf.
edu/ucsfhtml3.4/msfit.htm) and Mascot (Matrix Science,
http://www.matrixscience.com). The uninterpreted HPLC-
ESI/MS/MS data were analyzed by SEQUEST, a component
of the LCQ software and by Mascot.
3. Results
Table 1 shows the cell survival of human fibroblasts from
AD patients and age-matched controls. Ah25–35 was not
noticeably toxic to either the human fibroblasts from AD or
age-matched controls until more than 2 days had elapsed.
Both types of cells began to experience cytotoxicity after a
3-day incubation with Ah25–35, and the viability of the AD-
derived fibroblasts was significantly lower than controls
(P < 0.001 by ANOVA). Concurrent with cell survival
assays, the cells were visualized at 10 magnification by
light microscopy. Throughout the 4 days, untreated control
cells exhibited typical elongated, flat fibroblast morphology.
However, at day 3 and thereafter, some of the treated AD
cells began to exhibit morphological changes (e.g. became
spherical). Over half of the cells were dead after a 4-day
incubation with beta-amyloid.
The levels of ROS generated by Ah25–35 were similar in
fibroblasts from both AD and age-matched controls (Table
2). This indicates that fibroblasts from AD and controls do
not differ in their ability to take up the DCFH. The different
susceptibility of these cells to the oxidative stress does not
appear to be due to different levels of production of ROS by
Ah25–35.
In pilot studies, one-dimensional gel electrophoresis was
used to evaluate the level of oxidation of proteins after
incubating cells in the presence and absence of Ah25–35.
While the AD cells exhibited slightly greater levels of
oxidized proteins after 1 and 2 days, by day 3 the level of
oxidation of proteins in the fibroblasts from the AD subjects
was approximately threefold greater than from the controls
(data not shown).
In order to determine which specific proteins were
oxidized, we utilized 2-DE. Fig. 1A (left panel) shows a
typical example of a human skin fibroblast extract separated
by 2-DE (18-cm IPG strip: pH 5–6) and SyproR Ruby-
stained for total proteins. Fig. 1A (right panel) shows the
immunostained protein profile on the Western blot after
probing with anti-DNP antibody to detect the oxidized
proteins. Fig. 1B and C represents the immunostained
protein profiles from the area of magnification in Fig 1A,
right panel. Only a few of the proteins were oxidized and all
were located in the area defined by: pI = 5–6, MW=50–80
kDa. Fibroblasts from both AD and age-matched controls
showed basal levels of oxidation of these particular proteins
even when there was no exposure to Ah25–35. The level of
oxidation of these proteins in the fibroblasts from AD
subjects after exposure to Ah25–35 was increased 9- to 10-
fold from control levels for ‘‘a’’and ‘‘h’’, and 4.5-fold for
‘‘g’’ (Table 3). In contrast, the fibroblasts from age-matched
controls under the same conditions showed only an approx-
imate twofold increase in oxidation. This indicates that these
specific proteins are susceptible to oxidation in fibroblasts
from both AD and age-matched controls. However, the
levels of oxidation of all three proteins were much higher
in the fibroblasts from AD compared to the non-AD con-
trols. These three OSPs were excised from the gels and
identified by mass spectrometry. Two of the proteins (‘‘a’’
and ‘‘h’’) were identified as isoforms of heat shock protein
60 (HSP 60); the third OSP (‘‘g’’) was identified as
vimentin (Table 4).
4. Discussion
Elevated levels of beta-amyloid protein and its deposition
within the senile plaques of the brain are a hallmark of the
pathology of AD. Beta-amyloid has been shown to produce
ROS, which are believed to cause the accumulation of
oxidatively damaged proteins, which ultimately lead to
neuronal apoptosis [8,9]. Furthermore, the lesions in the
AD brain reveal oxidative damage by free radicals [5,6].
Beta-amyloid can exist in either soluble or fibril forms. The
Fig. 1. Effect of Ah25 – 35 treatment on specific protein oxidation. Exponentially dividing cells were dissociated with trypsin, and approximately 1106 cells
were plated into 100-mm plates and allowed to attach. Following a 3-day exposure of cells to 94 AM Ah25 – 35, both treated and nontreated cell extracts were
collected, then subjected to isoelectric focusing (18-cm IPG strips, pH 5–6) and molecular weight separation, as described in Materials and methods. Panel A
shows a 2-DE gel of a treated AD fibroblast sample that was SyproR Ruby-stained in order to visualize all proteins, and a blot immunostained with antibody
against DNP to visualize oxidized proteins having new DNP-reactive carbonyl groups. Panels B and C represent enlarged views of the area that shows the
highest intensity immunostaining: three specific oxidized proteins are highlighted (a, h, and g).
Table 3
Fig. 1, panels B Treatment Specific oxidation indexa
and C a h g
Control fibroblast none 60F 2 63F 26 214F 56
Control fibroblast 94 AM h-amyloid 132F 24 118F 30 472F 88
AD fibroblast none 55F 20 62F 18 246F 71
AD fibroblast 94 AM h-amyloid 559F 87 593F 94 1113F 215
a Specific oxidation index (e.g. nanomoles of carbonyl per milligram of
protein) [26].
Table 4
Protein identification using MALDI-TOF/MS
Spot name Protein MW (Da)/pI Identification (accession number)
a 61055/5.7 Heat shock protein 60 (284763)
h 61055/5.7 Heat shock protein 60 (284763)
g 53686/5.1 Vimentin (P08670)
Summary of the protein properties (theoretical isoelectric point and
molecular weight) and identification of proteins using MALDI-TOF.
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aggregated fibril form, which is self-generated from several
days of incubation of soluble form, exhibits greater cyto-
toxicity and increased production of ROS [21]. In our
studies, cells were not noticeably affected until after 2 days
of incubation with beta-amyloid. These results were
observed in the cell survival assay, in light microscopy,
and in analysis of levels of oxidized proteins. The measure-
ment of ROS produced inside cells showed a negligible
difference between nontreated and beta-amyloid treated
samples through the first 2 days of incubation with beta-
amyloid. However, after the third day of beta-amyloid
incubation, the levels of DCF-fluorescence were increased
in the beta-amyloid-treated cells compared to the nontreated
cells. This lag time may be due to the time required for the
formation of aggregated beta-amyloid (approximately 3
days) [22]. The levels of DCF-fluorescence, however, were
similar in fibroblasts from both AD and controls, indicating
no difference in ability to produce ROS inside cells by
Ah25–35. The different susceptibility (shown by cell sur-
vival, cell morphology, and protein oxidation) of Ah25–35-
treated fibroblasts from AD subjects, compared to age-
matched controls, suggests inherent differences in the AD
fibroblasts (e. g. diminished antioxidant capacity).
The most readily oxidized proteins (designated ‘‘a’’,
‘‘h’’, and ‘‘g’’) identified by mass spectrometry were HSP
60 (‘‘a’’ and ‘‘h’’) and vimentin (‘‘g’’). The two isoforms of
HSP 60 appear to differ only in charge (isoelectric point),
and thus are most likely produced by different degrees of
oxidation. HSP 60 plays a role as a mitochondrial chaperon
and its overexpression protects cells from apoptosis [23].
Vimentin is a critical cytoskeleton protein that is cleaved by
caspases at an early stage of apoptosis [24]. The over-
expression of caspase-resistant vimentin protects the cells
from apoptotic cell death caused by oxidative stresses in
vitro [25]. Thus, the two proteins, which appear to be most
easily oxidized in the human skin fibroblasts from AD
patients, are both antiapoptotic proteins. We also recently
observed that these two proteins appeared to be the primary
targets of H2O2-induced oxidative stress in neuronal cells
[26]. The oxidation of both HSP 60 and vimentin by either
H2O2 or Ah25–35 suggests that H2O2 may be the mediator of
the Ah25–35 toxicity. This would be consistent with pre-
vious reports of H2O2 production by beta-amyloid [27].
The involvement of oxidation in the induction of the
apoptosis is well established in both cell culture and animal
models [28,29]. By damaging specific proteins, such as
redox-sensitive regulatory proteins or apoptosis-related pro-
teins, oxidative stress can cause direct cell injury and alter
the cellular signaling system. For example, the transcription
factor NF-nB is bound to the inhibitory protein InB in the
cytoplasm. When cells are exposed to oxidative stress, InB
becomes oxidized and loses its inhibitory function, resulting
in the activation of NF-nB [30–37]. The identification of
such OSPs is critical for understanding the relationship
between oxidative stress and cell death, and perhaps the
underlying etiology of AD. Clearly, additional studies on
these particular OSPs and the reasons they are more suscep-
tible to oxidation in AD-derived cells are of major interest.
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